[Abstract] Objective: To explore the anti-tumor activity of MUC16-targeted chimeric antigen receptor modified NK-92 (CARNK-92) cells against ovarian cancer. Methods: The expression of MUC16 in surgically resected tumor tissues of 15 patients with ovarian cancer treated in the Department of Obstetrics and Gynecology of Qingyang Hospital of Traditional Chinese Medicine and 4 ovarian tumor cell lines was detected by Immunohistochemistry and Flow cytometry. MUC CAR sequence was synthesized by gene synthesis, and its lentivirus expression vector were constructed. CARNK-92 cells targeting MUC16 (MUC-BBz) were obtained by lentivirus infection. The expression of CD107a in MUC-BBz was detected by Flow cytometry. The activation of MUC-BBz cells and its cytotoxicity against SKOV3 target cells were characterized by the release of LDH assay. The xenograft nude mouse model of SKOV3 cells was established to verify the in vivo anti-tumor activity of MUC-BBz cells. Results: MUC16 was highly expressed in ovarian cancer tissues and human ovarian cancer cells. MUC-BBz was successfully constructed by infecting NK-92 cells with lentivirus, with a positive rate of (42.79±2.58)%. MUC-BBz could be specifically activated by MUC16 over-expressing tumor cells. After co-incubation of effector cells and target cells, the expression of CD107a on MUC-BBz was upregulated significantly (P<0.01), and the ability of MUC-BBz secreting cytokines IFN-γ and perforin also increased (all P<0.01). The LDH test indicated that with the increase of effector-target ratio, the cytotoxicity of MUC-BBz against 4 ovarian cancer cells (hey, COC1, SKOV3 and A2780) also significantly enhanced. The results of transplanted tumor model showed that transfusion of MUC-BBz could significantly inhibit the growth of SKOV3 xenograft in mice (P<0.01). Conclusion: The CARNK-92 cells can significantly inhibit the growth of ovarian cancer cells in vitro and in vivo, which provides an important basis for further evaluation of its clinical application.

[摘 要] 目的：探讨基于新型单载体SynNotch系统构建的局部分泌IL-2的CAR-T细胞（Syn.CD19.IL-2 CAR-T细胞）对传统CD19 CAR-T细胞功能的影响。方法：基于本课题组前期构建的单载体SynNotch系统，将CD19特异性FMC63抗体与IL-2表达模块整合，通过自失活逆转录病毒载体转导T细胞制备Syn.CD19.IL-2 CAR-T细胞。诱导验证实验分为Syn.CD19.IL-2 CAR-T细胞组和未转导T细胞组，通过ELISA检测抗原刺激后IL-2分泌水平。采用CFSE染色法检测在Syn.CD19.IL-2 CAR-T细胞存在时，CD19 CAR-T细胞与肿瘤Raji-Luc或SW620-CD19-Luc细胞共培养时，IL-2的分泌对CD19 CAR-T细胞增殖的影响。流式细胞术检测CD69表达，观察在Syn.CD19.IL-2 CAR-T细胞分泌IL-2的情况下，CD19 CAR-T细胞与Raji-Luc细胞共培养时的激活情况。结果：成功构建自失活逆转录病毒载体Syn.CD19.IL-2 CAR，制备出Syn.CD19.IL-2 CAR-T细胞，病毒滴度 > 1×107拷贝/mL，转导效率达37.1%。抗原刺激后，SynNotch CAR-T细胞IL-2分泌量显著高于未转导T细胞（P < 0.001）。在Syn.CD19.IL-2 CAR-T细胞分泌IL-2时，CD19 CAR-T细胞具有更强的增殖能力和更高的活化水平（均P < 0.001）。结论：成功构建的Syn.CD19.IL-2 CAR-T细胞能显著增强CD19 CAR-T细胞的增殖和活化能力。